Press Release: Basilea announces submission of -2-

tumor-infiltrating macrophages and improves response to T cell checkpoint

immunotherapy in pancreatic cancer models. Cancer Research 2014 (74),

5057-5069

7. E. Peranzoni, J. Lemoine, L. Vimeux et al. Macrophages impede CD8 T cells

from reaching tumor cells and limit the efficacy of anti--PD-1 treatment.

Proceedings of the National Academy of Science of the United States of

America 2018 (115), E4041-E4050

8. V. Mazzaferro, B. F. El-Rayes, M. Droz dit Busset et al. Derazantinib

(ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive

intrahepatic cholangiocarcinoma. British Journal of Cancer 2019 (120),

165-171. ClinicalTrials.gov identifier: NCT01752920

9. FIDES-01: ClinicalTrials.gov identifier: NCT03230318

10. FIDES-02: ClinicalTrials.gov identifier: NCT04045613

11. FIDES-03: ClinicalTrials.gov identifier: NCT04604132

12. J. Pohlmann, F. Bachmann, A. Schmitt-Hoffmann et al. BAL101553: An

optimized prodrug of the microtubule destabilizer B. M. Alexander, T. F.

Cloughesy. Adult Glioblastoma. Journal of Clinical Oncology 2017 (35),

2402-2409

13. ClinicalTrials.gov identifier: NCT02490800; C. Tiu, S. Derby, N. Md.

Haris et al. The potential utility of end-binding protein 1 (EB1) as

response-predictive biomarker for lisavanbulin: A phase 2 study of

lisavanbulin (BAL101553) in adult patients with recurrent glioblastoma.

Journal of Clinical Oncology 2021, 39 (15 supplement, TPS2068)

14. ClinicalTrials.gov identifier: NCT03250299

15. ClinicalTrials.gov identifier: NCT02895360

16. A. Sharmq, A. Broggini-Tenzer, V. Vuong et al. The novel microtubule

targeting agent BAL101553 in combination with radiotherapy in

treatment-refractory tumor models. Radiotherapy Oncology 2017 (124),

433-438

17. G. E. Duran, H. Lane, F. Bachmann et al. In vitro activity of the novel

tubulin active agent BAL27862 in MDR1(+) and MDR1(-) human breast and

ovarian cancer variants selected for resistance to taxanes. Cancer

Research 2010, 70 (8 supplement), abstract 4412

18. F. Bachmann, K. Burger, G. E. Duran et al. BAL101553 (prodrug of

BAL27862): A unique microtubule destabilizer active against drug

refractory breast cancers alone and in combination with trastuzumab.

Cancer Research 2014, 74 (19 supplement), abstract 831

19. A. Schmitt-Hoffmann, D. Klauer, K. Gebhardt et al. BAL27862: a unique

microtubule-targeted agent with a potential for the treatment of human

brain tumors. Molecular Cancer Therapeutics 2009, 8 (12 supplement), C233

20. A. C. Mladek, J. L. Pokorny, H. Lane et al. The novel tubulin-binding

'tumor checkpoint controller' BAL101553 has anti-cancer activity alone

and in combination treatments across a panel of GBM patient-derived

xenografts. Cancer Research 2016, 76 (14 supplement), abstract 4781

21. R. Bergès, A. Tchoghandjian, S. Honoré et al. The novel

tubulin-binding checkpoint activator BAL101553 inhibits EB1-dependent

migration and invasion and promotes differentiation of glioblastoma

stem-like cells. Molecular Cancer Therapeutics 2016 (15), 2740-2749

22. M. Skowronska, C. Tiu, A. Tzankov et al. Expression of end-binding

protein 1 (EB1), a potential response-predictive biomarker for

lisavanbulin, in glioblastoma and various other solid tumor types.

Journal of Clinical Oncology 2021, 39 (15 supplement, 3118)

23. A. E. Prota, F. Danel, F. Bachmann et al. The novel

microtubule-destabilizing drug BAL27862 binds to the colchicine site of

tubulin with distinct effects on microtubule organization. Journal of

Molecular Biology 2014 (426), 1848-1860

24. F. Bachmann, K. Burger, H. Lane. BAL101553 (prodrug of BAL27862): the

spindle assembly checkpoint is required for anticancer activity. Cancer

Research 2015, 75 (15 supplement), abstract 3789

Attachment

-- Press release (PDF)

https://ml-eu.globenewswire.com/Resource/Download/cfdabae7-9bc7-4e64-91cf-6512e4d08b3c

(END) Dow Jones Newswires

November 16, 2021 01:15 ET (06:15 GMT)